Author: Prati Pal Singh
Publisher: Springer Nature
ISBN: 9819923026
Category : Medical
Languages : en
Pages : 774
Get Book
Book Description
This book covers several important aspects of pharmaceutical research and innovations. It presents important topics on drug delivery, novel microsponge, nanocrystals, polymeric nanoparticles, peptide synthesis, biopharmaceuticals, pharmacodynamics, yeast flocculation, neuromodulators, innovative drug discovery, pharmacoinformatics, aminoquinoline, thiourea crystals for API synthesis, FDCs and formulations research, ayurveda and natural products, and innovations to militate anti-microbial resistance (AMR). A chapter is devoted to the applications of Artificial Intelligence and Machine Learning in diverse sectors of the pharmaceutical industry, including drug discovery and development, drug repurposing, and improving pharmaceutical productivity. The book also reviews the role of pharmacogenomics and pharmacogenetics in drug development and precision medicine. Further, the book presents an updated summary of recent advances in the fields of nanomedicines and nano-based drug delivery systems. This book is useful to pharmaceutical sciences students, researchers, educators, and professionals in the pharmaceutical industry to understand the intricacies of new drug research and innovations.
Author: Prati Pal Singh
Publisher: Springer
ISBN: 9789819923014
Category : Medical
Languages : en
Pages : 0
Get Book
Book Description
This book covers several important aspects of pharmaceutical research and innovations. It presents important topics on drug delivery, novel microsponge, nanocrystals, polymeric nanoparticles, peptide synthesis, biopharmaceuticals, pharmacodynamics, yeast flocculation, neuromodulators, innovative drug discovery, pharmacoinformatics, aminoquinoline, thiourea crystals for API synthesis, FDCs and formulations research, ayurveda and natural products, and innovations to militate anti-microbial resistance (AMR). A chapter is devoted to the applications of Artificial Intelligence and Machine Learning in diverse sectors of the pharmaceutical industry, including drug discovery and development, drug repurposing, and improving pharmaceutical productivity. The book also reviews the role of pharmacogenomics and pharmacogenetics in drug development and precision medicine. Further, the book presents an updated summary of recent advances in the fields of nanomedicines and nano-based drug delivery systems. This book is useful to pharmaceutical sciences students, researchers, educators, and professionals in the pharmaceutical industry to understand the intricacies of new drug research and innovations.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309498511
Category : Medical
Languages : en
Pages : 103
Get Book
Book Description
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
Author: Oliver Gassmann
Publisher: Springer Science & Business Media
ISBN: 3540247815
Category : Business & Economics
Languages : en
Pages : 178
Get Book
Book Description
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.
Author: Apostolos Zarros
Publisher: Frontiers Media SA
ISBN: 2889632237
Category :
Languages : en
Pages : 137
Get Book
Book Description
This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030904491X
Category : Medical
Languages : en
Pages : 225
Get Book
Book Description
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author: Ralph Landau
Publisher: Chemical Heritage Foundation
ISBN: 9780941901215
Category : Business & Economics
Languages : en
Pages : 442
Get Book
Book Description
Documents how science has provided an astonishing array of medicines for coping with human ailments. This volume addresses industry leaders, economic influences, and the development of individual products. It is suitable for policy makers, economists, corporate executives, research managers, and historians of science, technology, and medicine.
Author: Oliver Gassmann
Publisher: Springer
ISBN: 3319668331
Category : Business & Economics
Languages : en
Pages : 179
Get Book
Book Description
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: Congressional Budget Office
Publisher: Lulu.com
ISBN: 1304121445
Category :
Languages : en
Pages : 65
Get Book
Book Description
Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...
